Q1 2026 Twist Bioscience Corp Earnings Call Transcript
Key Points
- Twist Bioscience Corp (TWST) reported its 12th consecutive quarter of revenue growth, with a 17% year-over-year increase to $103.7 million.
- The company achieved a gross margin of 52.0% for the first quarter, an improvement of approximately four margin points over the previous year.
- Twist Bioscience Corp (TWST) has expanded its addressable market from $2 billion in 2020 to approximately $7 billion today, with expectations to reach $12 billion by 2030.
- The company is experiencing strong demand in AI-enabled discovery, contributing significantly to the 27% growth in DNA Synthesis & Protein Solutions revenue.
- Twist Bioscience Corp (TWST) is committed to reaching adjusted EBITDA breakeven by the fourth quarter of fiscal 2026, with a clear focus on revenue growth, gross margin, and disciplined investment.
- Operating expenses increased to $86.9 million, up from $77.5 million in the same period of 2025, driven by investments in commercial and digital capabilities.
- Adjusted EBITDA for the first quarter was a loss of approximately $13.4 million, although this was an improvement from the previous year.
- The diagnostics revenue remained flat year-over-year, with only a slight increase when excluding one large customer.
- The company is making significant investments in sales and digital infrastructure, which may temporarily moderate margin expansion.
- There is a reliance on a few large customers for a significant portion of revenue, which could pose risks if these customers reduce their orders.
Ladies and gentlemen, thank you for standing by. Welcome to Twist Bioscience Fiscal 2026 First Quarter Financial Results Conference Call. (Operator Instructions).
Please be advised that today's conference is being recorded. I would like now to turn the conference over to Angela Bitting, Senior Vice President of Corporate Affairs. Please go ahead.
Thank you, operator. Good morning, everyone. I would like to thank you for joining us for Twist Biosciences conference call to review our fiscal 2026 first quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbioscience.com. With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
